Clinical Nuclear Medicine

Skip Navigation LinksHome > April 2014 - Volume 39 - Issue 4 > Use of 111In-Pentetreotide Scan in a Subject With Treatment...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0000000000000326
Interesting Images

Use of 111In-Pentetreotide Scan in a Subject With Treatment Refractory Atypical Meningioma

Bural, Gonca G. MD*; Lieberman, Frank MD; Mountz, James M. MD, PhD*

Collapse Box


Abstract: A 57-year-old man with a history of multiple recurrent atypical meningiomas (World Health Organization grade II) had several surgical resections including γ knife resection of the parafalcine meningioma, followed with a stereotactic radiosurgical ablation. Despite these treatments, an MRI scan performed 7 months later showed progression of the disease. The patient remained symptomatic with intermittent severe headaches associated with nausea, vomiting, and visual disturbance. He had a positive 111In-pentetreotide indicating the presence of somatostatin receptors. Therefore, he was placed on systemic Sandostatin (octreotide acetate) treatment, and at follow-up, he was clinically responsive to treatment.

© 2014 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.